TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02046382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Study: NCT01493557
Drug: Pradaxa, within 30 minutes after a meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
Study: NCT01356225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN placebo
Study: NCT00404079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
Study: NCT00385658
Drug: Fluvastatin extended release, fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00385658
Drug: Fixed combination simvastatin/ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00624546
Drug: Prevacid Solutabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID Prevacid Solutabs
Study: NCT02702674
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch tablet containing no active drug material given before induction of labor
Study: NCT04270968
Drug: topical none steroidal anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
Study: NCT04236362
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT01890148
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral BD administration of 45 mg AZD5069
Study: NCT03979859
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03355066
Drug: SM08502
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM08502 tablets to be administered orally.
Study: NCT00682565
Drug: CK-1827452 24mg and 6 mg iv infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
Study: NCT00682565
Drug: CK-1827452 12.5mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg oral immediate release capsule
Study: NCT00682565
Drug: CK-1827452 48 mg and 11 mg iv infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
Study: NCT00682565
Drug: Placebo iv infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo iv infusion
Study: NCT00682565
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral immediate release capsule
Study: NCT00514761
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral vial
Study: NCT00514761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT04202952
Drug: HEC110114 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT00913328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo once daily
Study: NCT01219855
Drug: Cohort 1 CTAP101 Capsules- 60µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60µg of CTAP101 capsules given once daily for 42 days.
Study: NCT01219855
Drug: Cohort 1 CTAP101 Capsules - 90µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90µg of CTAP101 capsules given once daily for 42 days.
Study: NCT02593942
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1-0.5 mcg/kg/min infusion
Study: NCT02251067
Drug: Placebo to match VPI-2690B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00643669
Drug: AL-3789 Sterile Suspension
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration by anterior juxtascleral depot
Study: NCT00610714
Drug: AZD0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral once daily dose
Study: NCT02115763
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02115763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00398034
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04163458
Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in pre-filled pen, subcutaneous administration
Study: NCT04163458
Drug: MENOPUR powder and solvent for solution for injection, 75 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in vials (powder and diluent), subcutaneous administration
Study: NCT01248585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets taken once daily for 5 days
Study: NCT04315597
Drug: Laif® 900, BAY98-7108
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x daily, 1 tablet, 900 mg
Study: NCT04315597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x daily, 1 tablet, 900 mg
Study: NCT03213834
Drug: DNase
Normalized name: DNase
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Study: NCT01756404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
Study: NCT02956317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT00029926
Drug: 2-deoxy-2 [F-18] fluoro-2-d-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02050958
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00371566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04686383
Drug: CAL056 mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: 20 mg CAL056 mesylate/tablet
Study: NCT02233023
Drug: Bromocriptine and other dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01835899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI 1015550
Study: NCT00858637
Drug: Placebo of Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Study: NCT00858637
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Study: NCT00858637
Drug: Placebo of MCI-196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Study: NCT00604695
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of IV sterile saline
Study: NCT00318370
Drug: Chemo Plus Far
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
Study: NCT02448914
Drug: TRIGEL
Normalized name: Trigels F
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive TRIGEL. Treatment order is determined by randomization.
Study: NCT02918539
Drug: florbetapir F 18 PET scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
Study: NCT00608842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle placebo administered via intralipomal injection.
Study: NCT00308971
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
Study: NCT00308971
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for alpha lipoic acid; 2 pills daily for 4 months
Study: NCT00253929
Drug: Intra-arterial infusion of adenosine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00253929
Drug: intra-arterial infusion of caffeine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00253929
Drug: intra-arterial infusion of acetylcholine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01512108
Drug: oral anti-diabetic drug
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
Study: NCT03205176
Drug: AZD5153
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
Study: NCT01548066
Drug: Control placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Study: NCT00977587
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day
Study: NCT01290744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 12 months
Study: NCT01740557
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01188304
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeated daily doses
Study: NCT02982057
Drug: O.M.T
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00559221
Drug: FLAG+IDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cytarabine, G-CSF
Study: NCT02573740
Drug: ABT-957
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00869570
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
Study: NCT03380026
Drug: Valchlor 0.016 % Topical Gel
Normalized name: Valchlor 0.016 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply valchlor nightly on select lesions.
Study: NCT02855645
Drug: Trichosanthes root
Normalized name: Trichosanthes kirilowii root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
Study: NCT02855645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
Study: NCT04028141
Drug: Procedural sedation with ketofol in a 1 on 4 ratio
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years.
Study: NCT03209466
Drug: Placebo Comparator with physiological saline sterile solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
Study: NCT03468920
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
Study: NCT03468920
Drug: PO Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen PO 1000mg once pre-operatively
Study: NCT03468920
Drug: PO Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO placebo capsule compounded to match PO Acetaminophen capsule
Study: NCT03468920
Drug: IV Solution Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will serve as the placebo for the IV Acetaminophen intervention
Study: NCT02776059
Drug: Standard of care + pegfiltrastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
Study: NCT02776059
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone or pentoxifyline for 28 days only
Study: NCT01100359
Drug: liposome-encapsulated doxorubicin citrate
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01166425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
Study: NCT03030950
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: to give normal saline to the other group as a placebo
Study: NCT03873324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules
Study: NCT02542813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
Study: NCT00386243
Drug: Co-Analgesic Therapy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram
Study: NCT00386243
Drug: Opioid Analgesics
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
Study: NCT02781610
Drug: Standard of care IV antibiotic(s)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
Study: NCT00291486
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was administered orally at doses between 1000 and 1500 mg/m2/day depending on assigned dose level for 14 days per 21-day cycle. Daily doses were rounded to the nearest 150 mg.
Study: NCT04083651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
Study: NCT00281918
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous repeating dose
Study: NCT04345523
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for the treatment of COVID-19 in hospitalized patients
Study: NCT03658733
Drug: esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
Study: NCT03658733
Drug: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
Study: NCT06037135
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
Study: NCT01511016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
Study: NCT04627207
Drug: CKD-330 1 Tab. and D085 1 Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other names: Reference
Study: NCT00829114
Drug: ETHINYL ESTRADIOL AND LEVOGESTREL
Normalized name: desogestrel / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
Study: NCT04532775
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for intravenous and epidural injection
Study: NCT01939184
Drug: WC3055
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5, 25, 50 or 75 mg dose
Study: NCT01257672
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04638426
Drug: HL237 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A : HL237 100mg, twice a day, Treatment B : HL237 200mg, twice a day, Treatment C : HL237 400mg, twice a day
Study: NCT04638426
Drug: Placebo of HL237 tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of HL237, twice a day
Study: NCT00278746
Drug: Zinc and ORS
Normalized name: zinc gluconate Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
Study: NCT02183246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03722433
Drug: Placebo and sequential therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo without Vigiis 101-LAB component
Study: NCT03772262
Drug: Rosuvastatin Oral Tablet
Normalized name: rosuvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00703924
Drug: WR 279,396
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
Study: NCT00703924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
Study: NCT04205682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered BD for 5 days
Study: NCT00051909
Drug: LY451395
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199925
Drug: Gammaplex 5%
Normalized name: Gammaplex 5% 5g Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736670
Drug: Alcohol spray
Normalized name: Isopropyl Alcohol 70% Topical application Spray [ALCOHOL SPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00852787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously one time
Study: NCT04044339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered orally
Study: NCT01066741
Drug: Homeodent®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
Study: NCT00533299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
Study: NCT01400568
Drug: LPS challenge with nebulized LPS
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
Study: NCT01565681
Drug: ASP1240
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion